Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 5/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | CTSV | O60911 | 4/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14060028 | 0.81 | HPGD (0.44) | HPGDEPHX2POLBHTTALOX15 | |
| SCHEMBL10645430 | 0.80 | RAB9A (0.54) | MRGPRX4CTSBCTSLCTSKCTSV | |
| SCHEMBL11356407 | 0.79 | HPGD (0.62) | MRGPRX4HPGDCTSBEPHX2POLB | |
| SCHEMBL14059693 | 0.77 | HPGD (0.68) | HPGDKDM4EALDH1A1GAA | |
| SCHEMBL14060468 | 0.77 | HPGD (0.65) | HPGDPOLBHTTKDM4EALDH1A1 | |
| SCHEMBL14060463 | 0.77 | HPGD (0.63) | HPGDEPHX2POLBHTTKDM4E | |
| SCHEMBL14060151 | 0.75 | ALDH1A1 (0.53) | HPGDHTTKDM4EALDH1A1GAA | |
| SCHEMBL10645078 | 0.74 | GAA (0.50) | CTSBCTSLPOLBCTSKCTSV | |
| SCHEMBL23978781 | 0.73 | MAOA (0.53) | MRGPRX4EPHX2GAA | |
| SCHEMBL9873510 | 0.73 | CYP1A2 (0.56) | MRGPRX4CTSBHTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364466-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2714688-B1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8980911-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| WO-2012160464-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | MRGPRX4 1536/4885HPGD 608/4885CTSB 2957/4885 |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | MRGPRX4 1536/4885HPGD 608/4885CTSB 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.